Professional Summary

Professional Overview

Michael Wandell is an accomplished executive with over 40 years of experience in the biotechnology and pharmaceutical industries. He currently serves as the CEO of NeoTherma Oncology, a company developing innovative cancer treatments. Wandell's expertise spans clinical development, regulatory affairs, and quality management, with a focus on advancing novel therapies through the regulatory approval process.

Experience Summary

Current Role

As the CEO of NeoTherma Oncology, Wandell is leading the company's efforts to secure Series A financing to conduct a "First-in-Human" Investigational Device Exemption (IDE) study for their proprietary cancer treatment technology. In this role, he is responsible for strategic planning, fundraising, and overseeing the company's research and development activities.

Career Progression

Prior to his current role, Wandell held several senior leadership positions in the biotechnology and pharmaceutical sectors. He served as the President of the Kahler Glen Community Association, a position he held from 2011 to 2016. Wandell also worked as a Principal at CRQ Insight LLC, an entrepreneurial consulting firm, from 2010 to 2015. Additionally, he was an Entrepreneur-in-Residence at the Houston Area Translational Research Consortium (HATRC) from 2012 to 2014.

Earlier in his career, Wandell held senior roles at Epigenomics AG, where he served as the Senior Vice President of Clinical, Regulatory, and Quality, and at Sanofi Diagnostics Pasteur, where he was the Director of Clinical and Regulatory Affairs. He also gained experience in international clinical research at Syva Corporation.

Academic Background

Wandell holds a bachelor's degree, though the specific field of study is not provided in the background information.

Areas of Expertise

Wandell's extensive experience in the biotechnology and pharmaceutical industries has given him a deep understanding of clinical development, regulatory affairs, and quality management. He has a proven track record of navigating the complex regulatory landscape and advancing novel therapies through the approval process.

Professional Impact

Throughout his career, Wandell has made significant contributions to the development and commercialization of innovative medical technologies. As the CEO of NeoTherma Oncology, he is leading the company's efforts to secure funding for a groundbreaking cancer treatment, which has the potential to make a significant impact in the field of oncology.

Conclusion

With his extensive industry experience, strong leadership skills, and proven track record of success, Michael Wandell is well-positioned to guide NeoTherma Oncology through its next phase of growth and development. His focus on advancing novel therapies and his commitment to delivering innovative solutions to patients make him a valuable asset in the biotechnology and pharmaceutical industries.